RxDoctor Payments Data

Purushothaman Muthusamy, MD

Interventional Cardiology · Powell, TNNPI 1033473285

Payments from drug & device makers

$9,173in general payments, 2019–2025

Across 259 payments — averaging $35.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$4K
  • Edwards Lifesciences$1K
  • Novartis$997
  • Pfizer$486
  • Boehringer Ingelheim$217
  • Amgen$212
  • plus $2K from 27 others

What the payments were for

  • Travel & lodging$4,74952%
  • Food & beverage$4,41648%
  • Education$80%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,173 in reported general payments places this provider in the 50th percentile of 207 interventional cardiology providers in Tennessee.

See all interventional cardiology providers in Tennessee

Medicare billing

Part B allowed, 2024
$88,644
Medicare patients
494
Services billed
1,370

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban135$112,439
JardianceEmpagliflozin55$79,541
EntrestoSacubitril/Valsartan22$23,923
BrilintaTicagrelor23$15,055
VascepaIcosapent Ethyl16$6,523
CorlanorIvabradine Hcl12$6,327
Metoprolol Succinate313$3,102
Prasugrel Hcl30$2,066
Atorvastatin Calcium188$1,675
Potassium Chloride77$1,499
Amiodarone Hcl38$837
Diltiazem 24hr Er (Cd)Diltiazem Hcl47$831
Furosemide266$761
Flecainide Acetate36$673
Amlodipine Besylate154$666

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$486$112,439135 claims
Boehringer IngelheimJardiance$217$79,54155 claims
NovartisEntresto$997$23,92322 claims
AstraZenecaBrilinta$145$15,05523 claims
AmgenCorlanor$212$6,32712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 207 interventional cardiology providers in Tennessee.

Other interventional cardiology in Powell

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →